Reconnecting the Dots — Reinterpreting Industry–Physician Relations

Pharma Compliance Info Reconnecting the Dots — Reinterpreting Industry–Physician Relations Global

Lisa Rosenbaum, M.D., New England Journal of Medicine, May 7, 2015 Physician–industry interactions are common and diverse, ranging from the $10 bagel sandwich to the $1 million research grant.4 Although most observers agree that we must mitigate the risk of bias introduced by these relationships, the benefits wrought by interactions between physician-scientists and industry at the basic or translational research level are equally clear. The question, then, is how to best manage conflicts of interest while preserving the collaborations on which medical advances depend. To read the article by Lisa Rosenbaum, M.D.

Read More »

Australia | Public scrutiny of Big Pharma, doctor relationships

A new online database will reveal the perks doctors receive from drug companies. For decades pharmaceutical companies have been plying our doctors with all manner of perks and making generous payments to our specialists for speaking, consulting and advising. Defended as legitimate medical education, this promotion is decidedly unhealthy, evidence suggests, skewing prescriptions towards the latest and most expensive drugs even when older cheaper options are safer and more effective. And almost all of this has happened in secret with no public scrutiny. Until now. Under reforms just announced by the Australian Competition and Consumer Commission, drug companies will have …

Read More »

Australia | Pharmaceutical industry moves closer to improved transparency with ACCC Code authorisation

Medicines Australia CEO, Tim James, today welcomed the authorisation by the Australian Competition and Consumer Commission (ACCC) of the 18th Medicines Australia Code of Conduct, which requires reporting of payments by pharmaceutical companies to healthcare professionals for services or education. After a significant period of negotiation and discussion between the ACCC, Medicines Australia and key stakeholders, the authorisation of the Code is another step towards greater transparency as a result of industry leadership. The new Code will require Medicines Australia member companies to publicly report when a company pays a healthcare professional for a service or for educational purposes, including …

Read More »